Sermorelin
Also known as GHRH(1-29), Geref, GRF 1-29
Sermorelin is a synthetic peptide matching the first 29 amino acids of human growth hormone-releasing hormone, the shortest fully active fragment. It was approved in the US as Geref and discontinued by its manufacturer in 2008.
By [Author name]. Licensed pharmacist review: pending. Last updated .
Identity
- Structure
- GHRH(1-29)-NH2, 29 amino acids
- Molecular formula
- C149H246N44O42S (PubChem)
- Molar mass
- about 3,358 g/mol
- Former brand
- Geref (Serono)
- Half-life
- About 10 to 20 minutes after subcutaneous administration in published pharmacokinetic work.
What the research covers
Sermorelin was developed in the 1980s after GHRH was isolated, and was studied as a diagnostic test of pituitary growth hormone reserve and in children with growth hormone deficiency.
Its manufacturer stopped making Geref in 2008. FDA has stated that the withdrawal was not for reasons of safety or effectiveness.
Summaries describe what studies measured, not what a substance does for anyone. Nothing here is a claim of benefit or a basis for use.
Regulatory status
- No currently marketed FDA-approved sermorelin product.
- Because it was once approved, its compounding status differs from never-approved peptides. Rules depend on the 503A criteria; check with a pharmacist or FDA guidance. Research-grade sermorelin is not an approved product.
Anti-doping (WADA)
Prohibited at all times under S2 as a GHRH analog.
Follow changes on the FDA peptide status tracker.
Sermorelin questions
Why was sermorelin discontinued?
The manufacturer stopped producing Geref in 2008. FDA has indicated the discontinuation was not due to safety or effectiveness problems.